Navigation Links
Arthritis drugs safer than previously declared

A recently done review of findings published earlier, proves that the previous report exaggerated the risk that two drugs// show in raising the risk of cancer in those who use them.

Research done by Dr. Eric Matteson and colleagues at the Mayo Clinic in Rochester, New York in May 2006, dealing with the study of two drugs 'Humira' and 'Remicade' used currently by physicians to treat rheumatoid arthritis surfaced with findings that pointed out a heavy probability of development of cancer and infections like tuberculosis, in those who use them regularly.This information was was exhibited on labels according to the order of the FDA six months earlier.

However several teams of researchers have since then studied the same drugs all over again in a review to re affirm if they actually triple the chances of cancerous lesions and infections. Their review has projected new data which hints that risk of cancer is not as high as that was proclaimed in the previous studies. The Journal of the American Medical Association has published a number of letters from researchers who have reviewed the drugs again which claims that the use of drug Humira and Remicade only doubles the chances of carcinoma and may work against other auto immune diseases such as skin conditions such as psoriasis, ulcerative colitis.

Almost all the researchers, and the U.S. FDA feel in unison that it is the right of every to know about the risks but also opine that the benefits reflect that the drugs should stay on the market.

Matteson and his colleagues re did the analysis done in May and after considering certain data which were not analysed earlier reached the conclusion that the drugs may not triple the chances of cancer but only double the chances as these two drugs act on the auto immune system blocking the action of TNF-alpha one of the target compounds which mistakenly signals to the immune system to attack the joints as in rheumatoid arthritis.It is now an established fact that any drug that is capable of modifying the immune system can also cause cancer.

Another drug of the same class Enbrel is also being studied by researchers to look into possibilities of causing cancer or infections.

The market for drugs to treat Rheumatoid arthritis is on an upswing following the increase in number of Americans that are affected by rheumatoid arthritis according to the findings noted by market research company Research and Markets.

Related medicine news :

1. Another ray of hope for Arthritis Sufferers
2. Naked DNA Vaccination May Conquer Arthritis and Multiple Sclerosis
3. B Vitamin protects and lowers toxicity of Arthritis Drug
4. FDA Approves New Arthritis Drug, Bextra
5. Risk Of Developing Arthritis
6. Arthritis Drug May Cause Liver Damage
7. Arthritis drug can prolong life
8. New treatment for Rheumatoid Arthritis
9. Important cause of Arthritis
10. Personality Impacts Arthritis
11. New Rheumatoid Arthritis Treatment
Post Your Comments:

(Date:12/1/2015)... ... 01, 2015 , ... Growth in medical payments per workers’ compensation claim in ... hospital and nonhospital care, according to a recent study by the Workers Compensation Research ... , found medical payments per claim with more than seven days of lost time ...
(Date:12/1/2015)... ... December 01, 2015 , ... CloudLIMS today announced that ... Business Awards under the New Products and Services category for its innovative product ... management software that helps labs organize data and track samples with storage ...
(Date:12/1/2015)... New York, NY (PRWEB) , ... December 01, ... ... cause of non-traumatic limb amputations in the United States. Podiatrists are well aware ... (failure to adopt therapeutic behaviors) are often catastrophic contributors to diseases of the ...
(Date:12/1/2015)... ... December 01, 2015 , ... For the millions of ... Hollister Incorporated has launched the VaPro Plus Pocket™ touch free hydrophilic intermittent catheter. ... touch free catheter portfolio,” said Michael Gresavage, Vice President North America. "We designed ...
(Date:12/1/2015)... ... 01, 2015 , ... Next IT Healthcare, the leader in ... this year’s Fierce Innovation Awards: Healthcare Edition, an awards program from the publisher ... in the category of Digital Solutions for its innovative, industry-leading product, Alme Health ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Russia has always been a ... new drugs registered in Europe in 2015 were ... Russia has always been a country of choice ... in Europe in 2015 were tested in phase ... Russia has always been a country of choice for global ...
(Date:12/1/2015)... , Dec. 1, 2015 CytRx Corporation (NASDAQ: ... specializing in oncology, today announced that it has reached ... pivotal global Phase 3 clinical trial of aldoxorubicin in ... originally estimated to be completed in Q1 2016. The Phase ... under a Special Protocol Assessment from the FDA at ...
(Date:12/1/2015)... 1, 2015  The migration to value-based care ... care plans that help patients stay healthy and ... be digitally enabled, incorporate care guidelines and be ... They will also allow all stakeholders to collaborate ... is optimal. That is the vision, however, research ...
Breaking Medicine Technology: